Analysis on whether the medication must be continued after taking Rubitidine/Rubicatin (Zanbiga)

Lurbinectedin (Lurbinectedin), as an anti-tumor drug, is mainly used for the treatment of small cell lung cancer and some solid tumors. During use, whether the medication must be continued needs to be judged based on the patient's disease status and treatment goals. Generally speaking, rubitidine adopts a cyclic dosing schedule. After each cycle, doctors will evaluate whether to continue treatment based on tumor response and patient tolerance.

For patients who receive initial treatment, if the tumor responds well to the drug, doctors usually recommend continuing the drug as planned to maintain efficacy and delay disease recurrence. This is because rubitin controls the disease by inhibiting the transcription mechanism of tumor cells and inducing apoptosis. Stopping the drug too early may cause tumor cells to resume proliferation activity, thereby reducing the overall therapeutic effect.

However, if the patient experiences severe side effects or poor tolerance, the doctor may adjust the dosage or extend the medication interval, or even temporarily discontinue the medication. In this case, tumor indicators and the patient's overall condition need to be closely monitored so that treatment can be continued after side effects subside. Clinically, it is not recommended to stop medication on your own, otherwise it may increase the risk of disease recurrence and may miss the best treatment window.

In general, the principle of continued medication of rubitidine emphasizes individualization and dynamic adjustment. Patients should decide whether to continue taking the medication under the guidance of a professional doctor and based on efficacy evaluation and safety monitoring. Regular review of imaging and blood indicators can help doctors determine the length of treatment and medication intervals, thereby minimizing the occurrence of drug side effects while ensuring therapeutic efficacy.

Reference materials:https://www.drugs.com/